Ulisse Biomed Spa
MIL:UBM
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IT |
|
Ulisse Biomed Spa
MIL:UBM
|
19.5m EUR |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
388.4B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.4B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
179.9B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119.2B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.8B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
68B AUD |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
37.8B EUR |
Loading...
|
Market Distribution
| Min | -40 300% |
| 30th Percentile | 38.1% |
| Median | 52.1% |
| 70th Percentile | 67.8% |
| Max | 1 132% |
Other Profitability Ratios
Ulisse Biomed Spa
Glance View
Ulisse BioMed SpA is an Italian healthcare biotech company. The company is headquartered in Udine, Udine. The company went IPO on 2021-08-06. The firm focuses on creating new and transformative diagntostic platforms and products. The company creates diagnostic systems that can reach people directly and help increasing the frequency of health monitoring. Its platforms include Sagitta, NanoHybrid and Aptavir. Sagitta is a molecular diagnostics technology platform, capable of detecting and characterizing nucleic acids of viral, bacterial and eukaryotic origin. Sagitta is used to develop assays for Respiratory Viral Panel, Sexually Transmitted Diseases, Infectious Diseases and Oncology. NanoHybrid can be implemented not only to develop diagnostic solutions but also in the field of theranostics: the integration of a diagnostic method with a specific therapeutic intervention aimed at maximizing the effectiveness of the drug, as well as vaccine/immunoterapies monitoring. Aptavir is a platform for the identification and production of antiviral molecules.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Ulisse Biomed Spa is -86.9%, which is above its 3-year median of -795%.
Over the last 3 years, Ulisse Biomed Spa’s Gross Margin has increased from -375.6% to -86.9%. During this period, it reached a low of -2 340% on Dec 31, 2023 and a high of -86.9% on Jul 30, 2025.
